# US 2024/0002914 A1 · Probe-based analysis of nucleic acids and proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002914 A1
- Document ID: US20240002914A1
- Status: Published application
- Kind: A1
- Application number: 18/217,310
- Filed: 2023-06-30
- Published: 2024-01-04
- Earliest claimed: 2022-06-29
- Assignees: 10x Genomics, Inc.
- Applicants: 10x Genomics, Inc.
- Inventors: Katherine Pfeiffer; Andrew Scott Kohlway; Andrew John Hill; Paul Eugene Lund; Jawad N. Abousoud; Sharmila Chatterjee Bhattacharjee; Ryan Stott
- Web page: https://patentgrep.com/patent/US20240002914A1

## CPC

- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Q 1/6841: In situ hybridisation
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/1055: {Protein x Protein interaction, e.g. two hybrid selection}
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12N 15/1075: {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/85: for animal cells
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 33/5032: {on intercellular interactions}
- G01N 33/505: {involving T-cells}
- G01N 33/5304: {Reaction vessels, e.g. agglutination plates (for solid-phase systems G01N33/543)}
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/548: Carbohydrates, e.g. dextran
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- C12N 2320/10: in screening processes
- C12Q 2537/164: Methylation detection other then bisulfite or methylation sensitive restriction endonucleases
- C12Q 2563/179: the label being a nucleic acid
- C12Q 2563/185: Nucleic acid dedicated to use as a hidden marker/bar code, e.g. inclusion of nucleic acids to mark art objects or animals
- C12Q 2565/1015: labels being on the same oligonucleotide
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C40B 70/00: Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or bar codes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

Provided herein are systems and methods for processing biomolecules (e.g., nucleic acid molecules, proteins) from a sample. A method for processing biomolecules may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule) and barcoding the probe-nucleic acid molecule complex or derivatives thereof. Such a method can comprise performing a nucleic acid reaction, e.g., extension, denaturation, and amplification. A method for processing a sample may comprise hybridizing probes to (i) target regions of a nucleic acid molecule (e.g., RNA molecule) and (ii) a reporter oligonucleotide of a feature binding group, and barcoding the probe-associated molecules. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well.

## Claims

### Claim 1

A method for analyzing a nucleic acid molecule of an embedded, fixed tissue, comprising:
(a) providing the embedded, fixed tissue, wherein:
(i) the embedded, fixed tissue comprises a plurality of cells,
(ii) a cell of the plurality of cells comprises the nucleic acid molecule, and
(iii) the embedded, fixed tissue is embedded in a solid medium;
(b) removing at least a portion of the solid medium from the embedded, fixed tissue, thereby obtaining a fixed tissue comprising the plurality of cells;
(c) dissociating the fixed tissue into cells of the plurality of cells, wherein the cells comprise the cell comprising the nucleic acid molecule; and
(d) in the cell, using a barcode molecule to generate a barcoded nucleic acid molecule comprising a barcode sequence and a sequence corresponding to the nucleic acid molecule.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fixed tissue is fixed at least about 1 year prior to (a).

### Claim 3 (depends on 2)

The method of claim 2, wherein the fixed tissue is fixed at least about 5 years prior to (a).

### Claim 4 (depends on 1)

The method of claim 1, further comprising, in (b), adding a first solvent to the embedded, fixed tissue, thereby dissolving the solid medium, thereby obtaining a tissue.

### Claim 5 (depends on 4)

The method of claim 4, wherein the first solvent is a non-polar solvent.

### Claim 6 (depends on 5)

The method of claim 5, wherein the non-polar solvent comprises xylene.

### Claim 7 (depends on 5)

The method of claim 5, wherein the non-polar solvent comprises Neo-Clear® xylene alternative.

### Claim 8 (depends on 4)

The method of claim 4, further comprising removing the first solvent from the tissue.

### Claim 9 (depends on 8)

The method of claim 8, further comprising adding a second solvent to the tissue.

### Claim 10 (depends on 9)

The method of claim 9, wherein the second solvent is a polar solvent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the polar solvent comprises ethanol.

### Claim 12 (depends on 9)

The method of claim 9, further comprising removing the second solvent from the tissue.

### Claim 13 (depends on 12)

The method of claim 12, further comprising adding a rehydration agent to the tissue.

### Claim 14 (depends on 13)

The method of claim 13, wherein the rehydration agent comprises water.

### Claim 15 (depends on 13)

The method of claim 13, further comprising removing the rehydration agent from the tissue.

### Claim 16 (depends on 15)

The method of claim 15, further comprising adding buffer to the tissue.

### Claim 17 (depends on 16)

The method of claim 16, further comprising removing the buffer from the tissue.

### Claim 18 (depends on 17)

The method of claim 17, further comprising, in (c), dissociating the tissue.

### Claim 19 (depends on 18)

The method of claim 18, further comprising resuspending the tissue in a supernatant.

### Claim 20 (depends on 19)

The method of claim 19, further comprising filtering the tissue.

### Claim 21 (depends on 20)

The method of claim 20, further comprising washing the tissue.

### Claim 22 (depends on 21)

The method of claim 21, further comprising resuspending the tissue.

### Claim 23 (depends on 18)

The method of claim 18, wherein the dissociating the tissue is performed using an automated dissociator.

### Claim 24 (depends on 23)

The method of claim 23, wherein said automated dissociator is a gentleMACS™ Octo Dissociator.

### Claim 25 (depends on 18)

The method of claim 18, wherein the dissociating the tissue is performed using a manual pulverizer.

### Claim 26 (depends on 1)

The method of claim 1, wherein (b) and (c) provide a yield of cells of at least about 1×105 cells per two 25 micrometer sections of the fixed tissue.

### Claim 27 (depends on 1)

The method of claim 1, wherein the fixed tissue comprises fixed human tissue.

### Claim 28 (depends on 27)

The method of claim 27, wherein the fixed tissue comprises one or more of fixed connective tissue, fixed epithelial tissue, fixed organ tissue, fixed muscle tissue, fixed ligaments, fixed tendons, fixed skin tissue, fixed breast tissue, fixed bladder tissue, fixed kidney tissue, fixed liver tissue, fixed colon tissue, fixed thyroid tissue, fixed cervical tissue, fixed prostate tissue, fixed lung tissue, fixed cardiac tissue, fixed heart tissue, fixed muscle tissue, fixed pancreas tissue, fixed anal tissue, fixed bile duct tissue, fixed a bone tissue, fixed bone marrow, fixed uterine tissue, fixed ovarian tissue, fixed endometrial tissue, fixed vaginal tissue, fixed vulvar tissue, fixed stomach tissue, fixed ocular tissue, fixed nasal tissue, fixed sinus tissue, fixed penile tissue, fixed salivary gland tissue, fixed gut tissue, fixed gallbladder tissue, fixed gastrointestinal tissue, fixed bladder tissue, fixed brain tissue, fixed spinal tissue, fixed neurons, fixed cells representative of a blood-brain barrier, fixed blood, fixed hair, fixed nails, fixed keratin, or fixed collagen.

### Claim 29 (depends on 1)

The method of claim 1, wherein (d) comprises hybridizing the barcode molecule to the nucleic acid molecule.

### Claim 30 (depends on 29)

The method of claim 29, further comprising extending the barcode molecule to form the barcoded nucleic acid molecule.
